{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:33:15Z","timestamp":1793338395179,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA142543"],"award-info":[{"award-number":["P30CA142543"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR220088"],"award-info":[{"award-number":["RR220088"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jconrel.2026.115351","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:44:16Z","timestamp":1789515856000},"page":"115351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PA","title":["B-cell maturation antigen -targeted Tirapazamine-loaded liposomes overcome hypoxia-induced drug resistance and metastasis in multiple myeloma"],"prefix":"10.1016","volume":"399","author":[{"given":"Mina","family":"Maksimos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Muz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feda","family":"Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimaz","family":"Afrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurbakhash","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel Kareem","family":"Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115351_bb0005","author":"Society AC"},{"key":"10.1016\/j.jconrel.2026.115351_bb0010","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1182\/blood.V122.21.5359.5359","article-title":"Multiple myeloma in patients under 40 years old is associated with high-risk features and worse outcomes","volume":"122","author":"Costello","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115351_bb0015","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.3324\/haematol.2020.259093","article-title":"The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database","volume":"106","author":"Cherniawsky","year":"2021","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115351_bb0020","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin. Proc."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115351_bb0025","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","article-title":"Analysis of real-world data on overall survival in multiple myeloma patients with \u22653 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD","volume":"21","author":"Usmani","year":"2016","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115351_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020407","article-title":"Multiple myeloma: available therapies and causes of drug resistance","volume":"12","author":"Pinto","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115351_bb0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000488423","article-title":"Different adaptive responses to hypoxia in Normal and multiple myeloma endothelial cells","volume":"46","author":"Filippi","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.jconrel.2026.115351_bb0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/HP.S93413","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"3","author":"Muz","year":"2015","journal-title":"Hypoxia (Auckl.)"},{"issue":"10","key":"10.1016\/j.jconrel.2026.115351_bb0045","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1541-7786.MCR-14-0028","article-title":"The role of hypoxia and exploitation of the hypoxic environment in hematologic malignancies","volume":"12","author":"Muz","year":"2014","journal-title":"Mol. Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115351_bb0050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/15384047.2016.1276137","article-title":"Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy","volume":"18","author":"Imai","year":"2017","journal-title":"Cancer Biol. Ther."},{"issue":"24","key":"10.1016\/j.jconrel.2026.115351_bb0055","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1182\/blood-2011-09-380410","article-title":"Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jconrel.2026.115351_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.82","article-title":"Hypoxia promotes stem cell-like phenotype in multiple myeloma cells","volume":"4","author":"Muz","year":"2014","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115351_bb0065","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1080\/10428194.2017.1319052","article-title":"Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance","volume":"58","author":"Muz","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115351_bb0070","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.3324\/haematol.2018.194688","article-title":"PYK2\/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma","volume":"104","author":"Muz","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115351_bb0075","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.tranon.2017.04.010","article-title":"Selinexor overcomes hypoxia-induced drug resistance in multiple myeloma","volume":"10","author":"Muz","year":"2017","journal-title":"Transl. Oncol."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115351_bb0080","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3109\/10428194.2015.1099645","article-title":"Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma","volume":"57","author":"de la Puente","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115351_bb0085","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/leu.2012.353","article-title":"The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression","volume":"27","author":"Azab","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115351_bb0090","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1541-7786.MCR-14-0150","article-title":"Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenstrom macroglobulinemia","volume":"13","author":"Muz","year":"2015","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115351_bb0095","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/15384047.2019.1665405","article-title":"CXCR4-targeted PET imaging using (64)Cu-AMD3100 for detection of Waldenstrom Macroglobulinemia","volume":"21","author":"Muz","year":"2020","journal-title":"Cancer Biol. Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115351_bb0100","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00280-015-2920-7","article-title":"Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs","volume":"77","author":"Phillips","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.115351_bb0105","article-title":"Targeting hypoxia: hypoxia-activated prodrugs in cancer therapy","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115351_bb0110","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/0360-3016(86)90267-1","article-title":"SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells","volume":"12","author":"Zeman","year":"1986","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115351_bb0115","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/0006-2952(88)90010-X","article-title":"Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233)","volume":"37","author":"Laderoute","year":"1988","journal-title":"Biochem. Pharmacol."},{"issue":"16","key":"10.1016\/j.jconrel.2026.115351_bb0120","first-page":"4473","article-title":"Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation","volume":"52","author":"Wang","year":"1992","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115351_bb0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/157488406775268192","article-title":"Tirapazamine: from bench to clinical trials","volume":"1","author":"Marcu","year":"2006","journal-title":"Curr. Clin. Pharmacol."},{"issue":"19","key":"10.1016\/j.jconrel.2026.115351_bb0130","first-page":"4460","article-title":"Use of the comet assay to identify cells sensitive to tirapazamine in multicell spheroids and tumors in mice","volume":"56","author":"Olive","year":"1996","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115351_bb0135","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0304-3835(96)04292-9","article-title":"Tirapazamine (SR 4233) interrupts cell cycle progression and induces apoptosis","volume":"105","author":"Lin","year":"1996","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2026.115351_bb0140","first-page":"62","article-title":"Hypoxia-activated prodrugs and (lack of) clinical progress: the need for hypoxia-based biomarker patient selection in phase III clinical trials","volume":"15","author":"Spiegelberg","year":"2019","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115351_bb0145","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/ejh.12870","article-title":"Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma","volume":"98","author":"de la Puente","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jconrel.2026.115351_bb0150","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jconrel.2017.11.045","article-title":"Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma","volume":"270","author":"de la Puente","year":"2018","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115351_bb0155","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1038\/s41467-020-19932-1","article-title":"Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma","volume":"11","author":"Federico","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115351_bb0160","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41408-023-00828-4","article-title":"E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma","volume":"13","author":"Maksimos","year":"2023","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115351_bb0165","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.3324\/haematol.2016.142190","article-title":"Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma","volume":"101","author":"de la Puente","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115351_bb0170","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/1078-0432.CCR-11-0111","article-title":"Eph-B2\/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom\u2019s macroglobulinemia","volume":"18","author":"Azab","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115351_bb0175","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.12734","article-title":"PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance","volume":"165","author":"Azab","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115351_bb0180","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood-2009-01-199281","article-title":"RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma","volume":"114","author":"Azab","year":"2009","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.jconrel.2026.115351_bb0185","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1182\/blood-2008-10-186668","article-title":"CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy","volume":"113","author":"Azab","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jconrel.2026.115351_bb0190","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1182\/blood-2014-02-558742","article-title":"CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma","volume":"124","author":"Azab","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115351_bb0195","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/417586","article-title":"Inhibition of P-selectin and PSGL-1 using humanized monoclonal antibodies increases the sensitivity of multiple myeloma cells to Bortezomib","volume":"2015","author":"Muz","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115351_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122853","article-title":"Bispecific T cell engagers for the treatment of multiple myeloma: achievements and challenges","volume":"13","author":"Alhallak","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"19","key":"10.1016\/j.jconrel.2026.115351_bb0205","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.18632\/oncotarget.28054","article-title":"Nanoparticle T cell engagers for the treatment of acute myeloid leukemia","volume":"12","author":"Alhallak","year":"2021","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.jconrel.2026.115351_bb0210","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1038\/s41375-021-01127-2","article-title":"Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy","volume":"35","author":"Alhallak","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.jconrel.2026.115351_bb0215","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1007\/s11095-015-1718-y","article-title":"Advancements in tumor targeting strategies for boron neutron capture therapy","volume":"32","author":"Luderer","year":"2015","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115351_bb0220","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jconrel.2007.07.014","article-title":"Prevention of tumor recurrence and distant metastasis formation in a breast cancer mouse model by biodegradable implant of 131I-norcholesterol","volume":"123","author":"Azab","year":"2007","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115351_bb0225","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11095-007-9330-4","article-title":"The metastatic stage-dependent mucosal expression of sialic acid is a potential marker for targeting colon cancer with cationic polymers","volume":"25","author":"Azab","year":"2008","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115351_bb0230","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.ijrobp.2020.11.052","article-title":"Localized delivery of cisplatin to cervical cancer improves its therapeutic efficacy and minimizes its side effect profile","volume":"109","author":"Federico","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115351_bb0235","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11095-019-2670-z","article-title":"Thermal sensitive liposomes improve delivery of boronated agents for boron neutron capture therapy","volume":"36","author":"Luderer","year":"2019","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115351_bb0240","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1182\/blood-2011-07-368050","article-title":"P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115351_bb0245","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-2443.1996.05005.x","article-title":"Phosphorylation of Ser-3 of cofilin regulates its essential function on actin","volume":"1","author":"Moriyama","year":"1996","journal-title":"Genes Cells"},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2026.115351_bb0250","article-title":"Cell trafficking in multiple myeloma","volume":"3","author":"Bianchi","year":"2012","journal-title":"Open J. Hematol."},{"issue":"25","key":"10.1016\/j.jconrel.2026.115351_bb0255","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1182\/blood-2011-07-368142","article-title":"Canonical and noncanonical hedgehog pathway in the pathogenesis of multiple myeloma","volume":"120","author":"Blotta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115351_bb0260","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.biomaterials.2015.09.017","article-title":"3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma","volume":"73","author":"de la Puente","year":"2015","journal-title":"Biomaterials"},{"issue":"26","key":"10.1016\/j.jconrel.2026.115351_bb0265","doi-asserted-by":"crossref","first-page":"6860","DOI":"10.1182\/blood-2011-03-342394","article-title":"Defining the role of TORC1\/2 in multiple myeloma","volume":"118","author":"Maiso","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115351_bb0270","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI66517","article-title":"BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression","volume":"123","author":"Roccaro","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115351_bb0275","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/ajh.23814","article-title":"Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib","volume":"89","author":"Sahin","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115351_bb0280","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/blood-2007-12-129395","article-title":"SDF-1\/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia","volume":"112","author":"Ngo","year":"2008","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jconrel.2026.115351_bb0285","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1182\/blood-2010-06-292243","article-title":"Integrin beta7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion","volume":"117","author":"Neri","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jconrel.2026.115351_bb0290","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41419-022-05421-4","article-title":"An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma","volume":"13","author":"Darawshi","year":"2022","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115351_bb0295","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.celrep.2015.06.059","article-title":"CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation","volume":"12","author":"Roccaro","year":"2015","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115351_bb0300","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2012-01-379024","article-title":"Myeloma as a model for the process of metastasis: implications for therapy","volume":"120","author":"Ghobrial","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115351_bb0305","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.13927","article-title":"A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma","volume":"173","author":"Muz","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115351_bb0310","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/jcmm.16885","article-title":"Liposomal phytohemagglutinin: in vivo T-cell activator as a novel pan-cancer immunotherapy","volume":"26","author":"Alhallak","year":"2022","journal-title":"J. Cell. Mol. Med."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2026.115351_bb0315","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2005.03.015","article-title":"Targeting normal and neoplastic tissues in the rat jejunum and colon with boronated, cationic acrylamide copolymers","volume":"106","author":"Azab","year":"2005","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115351_bb0320","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115351_bb0325","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.jconrel.2026.115351_bb0330","first-page":"S13","article-title":"Bispecific T-cell engagers for treatment of multiple myeloma","volume":"98","author":"Ravi","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"21","key":"10.1016\/j.jconrel.2026.115351_bb0335","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/1078-0432.CCR-22-0618","article-title":"FDA approval summary: Belantamab Mafodotin for patients with relapsed or refractory multiple myeloma","volume":"28","author":"Baines","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115351_bb0340","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115351_bb0345","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1517\/13543780903114168","article-title":"Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin","volume":"18","author":"Boulikas","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"12","key":"10.1016\/j.jconrel.2026.115351_bb0350","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","article-title":"A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles","volume":"24","author":"Waterhouse","year":"2001","journal-title":"Drug Saf."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115351_bb0355","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/ajh.25627","article-title":"Phase I\/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed\/refractory multiple myeloma","volume":"94","author":"Ghobrial","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115351_bb0360","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-019-0227-3","article-title":"Inhibition of E-selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy","volume":"9","author":"Muz","year":"2019","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115351_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210082","article-title":"Perspectives for improving the tumor targeting of nanomedicine via the EPR effect in clinical tumors","volume":"24","author":"Kim","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926007558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926007558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:17:12Z","timestamp":1793337432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926007558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":73,"alternative-id":["S0168365926007558"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115351","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B-cell maturation antigen -targeted Tirapazamine-loaded liposomes overcome hypoxia-induced drug resistance and metastasis in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115351"}}